KR20210038874A - 파킨슨 병 치료에서의 만누론 이산 조성물의 용도 - Google Patents

파킨슨 병 치료에서의 만누론 이산 조성물의 용도 Download PDF

Info

Publication number
KR20210038874A
KR20210038874A KR1020217001708A KR20217001708A KR20210038874A KR 20210038874 A KR20210038874 A KR 20210038874A KR 1020217001708 A KR1020217001708 A KR 1020217001708A KR 20217001708 A KR20217001708 A KR 20217001708A KR 20210038874 A KR20210038874 A KR 20210038874A
Authority
KR
South Korea
Prior art keywords
composition
total weight
mannuron
mannuron diacid
diacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217001708A
Other languages
English (en)
Korean (ko)
Inventor
메이유 장
시안리앙 신
시아오퀑 두
젠킹 장
지안 딩
Original Assignee
상하이 그린벨리 파머수티컬 주식회사
상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 그린벨리 파머수티컬 주식회사, 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 filed Critical 상하이 그린벨리 파머수티컬 주식회사
Publication of KR20210038874A publication Critical patent/KR20210038874A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217001708A 2018-06-29 2019-06-28 파킨슨 병 치료에서의 만누론 이산 조성물의 용도 Ceased KR20210038874A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810713411.3A CN110652516A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN201810713411.3 2018-06-29
PCT/CN2019/093803 WO2020001640A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用

Publications (1)

Publication Number Publication Date
KR20210038874A true KR20210038874A (ko) 2021-04-08

Family

ID=68984646

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001708A Ceased KR20210038874A (ko) 2018-06-29 2019-06-28 파킨슨 병 치료에서의 만누론 이산 조성물의 용도

Country Status (7)

Country Link
US (1) US11406654B2 (https=)
EP (1) EP3815691A4 (https=)
JP (1) JP2021528460A (https=)
KR (1) KR20210038874A (https=)
CN (1) CN110652516A (https=)
AU (1) AU2019296851A1 (https=)
WO (1) WO2020001640A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796243B (zh) * 2021-01-27 2024-04-05 中国海洋大学 一种甘露糖醛酸和益母草碱的药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562050A (zh) * 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
CN101301310B (zh) * 2007-05-08 2011-11-02 首都医科大学 褐藻多糖硫酸酯在预防和治疗帕金森病中的用途
US20140371283A1 (en) * 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN103405468B (zh) * 2013-08-16 2015-08-19 中国海洋大学 一种低分子量甘露糖醛酸寡糖在制备预防或治疗帕金森症的药物或保健品中的应用
CN103800348B (zh) * 2014-03-13 2015-07-01 中国科学院海洋研究所 甘露葡萄糖醛酸寡糖在制备治疗或预防帕金森病和/或老年痴呆药物和/或保健品中的应用
CN103948611B (zh) * 2014-03-31 2016-03-02 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
JP6977059B2 (ja) * 2016-12-30 2021-12-08 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドShanghai Green Valley Pharmaceutical Co., Ltd. マンヌロン二酸の組成物

Also Published As

Publication number Publication date
WO2020001640A1 (zh) 2020-01-02
US20210260089A1 (en) 2021-08-26
US11406654B2 (en) 2022-08-09
AU2019296851A8 (en) 2021-07-01
EP3815691A4 (en) 2022-04-27
JP2021528460A (ja) 2021-10-21
EP3815691A1 (en) 2021-05-05
AU2019296851A1 (en) 2021-01-28
CN110652516A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
US11406659B2 (en) Use of mannuronic diacid composition in treatment of inflammation
KR20210038874A (ko) 파킨슨 병 치료에서의 만누론 이산 조성물의 용도
KR20210038875A (ko) 당뇨병 치료에서의 만누론 이산 조성물의 용도
US11406653B2 (en) Use of mannuronic diacid composition in treatment of pain
KR20210040039A (ko) 혈관성 치매 치료에서의 만누론 이산 조성물의 용도
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation
JP2022543641A (ja) Ｔｈ１優位関連疾患の治療におけるマンヌロン酸オリゴ糖またはそれを含んでなる組成物の使用
HK40014916A (en) Use of a composition of oligomeric mannuronic diacid for treating vascular dementia
EA041420B1 (ru) Композиции маннуроновой дикислоты, способы ее получения и использования

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220405

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240826

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241101

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D